Overview

Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

Status:
Completed

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

Effects of fulvestrant on the ERs may be evaluable by molecular imaging using positron emission tomography with the ER-specific FES tracer. In this study we will determine the utility of FES-PET in the prediction of response to fulvestrant 500 mg in women with estrogen positive metastatic breast cancer

Phase:

N/A

Details

Lead Sponsor:

Zhimin Shao

Treatments:

Estradiol
Estrogens
Fulvestrant